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Diagnostic tests for human immunodeficiency virus first became commercially available in
1985, only two yearsafter theviruswasdiscovered. In the short period oftimesince then, we have
witnessed improvements in antibody detection methods, refinements in culture techniques, and
the introduction of antigen and nucleic acid detection methods, including the polymerase chain
reaction. These diagnostic tools as well as their advantages and disadvantages arereviewed in this
report.
INTRODUCTION
Routine screening and diagnosis of human immunodeficiency virus type 1 (HIV-1)
started in 1985 with the introduction of the enzyme-linked immunosorbent assay
(ELISA) for antibody detection, only two years after the initial isolation of the
etiologic agent for the acquired immune deficiency syndrome (AIDS). Since then,
dramatic improvements in methods ofdiagnosis have rapidly been introduced, such as
refined isolation and antibody detection methods, antigen detection, and nucleic acid
detection (Table 1). This paper reviews the developments that have occurred from the
viewpoint ofa director ofa large diagnostic virology laboratory.
ISOLATION AND CULTIVATION OF HIV-1
Original Discovery
In the first reports ofisolation ofHIV-1 [1,2], Tcells from the peripheral blood ofan
AIDS patient and from the lymph node biopsy of a homosexual with generalized
lymphadenopathy were cultivated in vitro in medium containing human T-cell growth
factor (TCGF), which is now referred to as interleukin 2. Virus was visualized in these
cultured cells by electron microscopy, and virus-specific reverse transcriptase (RT)
was detected in the culture medium. The virus was then transmitted in vitro to T cells
derived from cord blood of newborns or healthy adult donors, using co-cultivation
techniques. Barre-Sinoussi et al. [1] included phytohemagglutinin (PHA) in the
culture medium for three days to stimulate the T cells to divide, antiserum to human
alpha interferon to neutralize endogenous interferon, and polybrene (2 mcg/ml) to aid
virus adsorption to uninfected T cells.
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TABLE 1
Diagnostic Techniques for HIV-1
Initial Current Status Reference
Method Use Description (1988-1989) Cited
Isolation and culture 1983 Growth and detection Clinical diagnosis [1,2]
of HIV-1 ofvirus in living
cells
Antibody detection
ELISA using 1985 Detection ofantibody Routine blood screen- [26]
cell culture anti- ing and clinical di-
gen agnosis
Western blot 1985 Confirmation ofanti- Routine confirmation [27,28]
body detected ofELISA
Immunofluores- 1985 Detection ofantibody Limited use [29,30,31,32,33,34,35]
cence, hemag-
glutination,
radioimmuno-
precipitation,
and so on
ELISA using 1986 Detection ofantibody Research [43,44]
recombinant an-
tigen or syn-
thetic peptide
Antigen detection 1986 Detection ofviral anti- Research [50,51,52,53]
gen
Nucleic acid detec- 1987 Detection ofviral nu- Research [57,58,59]
tion cleic acid
Problems andDifficulties
Shortage ofTrainedPersonnel The method ofco-cultivation with fresh human
peripheral blood lymphocytes (PBL) and detection of virus by assay for RT were
unfamiliar techniques to most diagnostic virologists [3,4]. Only researchers who had
worked on avian or murine retroviruses were proficient in these techniques [5,6]. Thus,
in 1985, the Centers for Disease Control (CDC) offered courses to train technologists
in HIV-1 culture [7] and theCalifornia State Health Department produced aguidefor
culture techniques [8]. This guide helped many laboratories to become established;
however, since HIV-1 infections can lead to AIDS with its high mortality rate, few
technologists were willing to work with this virus. Subsequent reports of a few cases
oflaboratory-acquired infection showed that the danger was real, although slight
[9,10].
Turnaround Time In addition to the specialized techniques and the risk
ofworking with HIV-1, the isolation of HIV is a lengthy process. Although the
majority ofcultures for HIV-1 become positivewithin about ten days, cultures must be
maintained and tested for at least four weeks before being considered negative [7,1 1].
Lack ofEstablished Cell Linesfor Culture One of the early breakthroughs in
HIV research was the discovery of the H9 cell line, which was capable of replicating
HIV-1 to high titer [3]. Unfortunately, early work at CDC and elsewhere showed that
this cell line and others were not as sensitive as primary PBL for initial isolation of
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HIV-1 from clinical specimens [7,12]. The logistical problems of isolating HIV from
clinical specimens involved, first, obtaining fresh PBL from healthy donors (negative
for antibody to HIV-1 and hepatitis B); second, establishing the PBL in culture by
stimulation with PHA for three days; and, finally, maintaining the stimulated cells in
culture in preparation for co-cultivation attempts. Stimulated PBL were also needed
for the weekly refeeding ofthe ongoing cultures.
Expense Isolation ofHIV-1 is an expensive procedure. Therefore, the use ofthis
test as a diagnostic tool can only be justified for highly specific reasons. Laboratories
routinely charge $400 to $500 for the service. The reasons for this high cost include the
need for expensive equipment and reagents, as well as skilled technical help, and the
labor-intensive nature ofthe technique.
Culture requires a separate isolation room with a biological safety cabinet (Class
II), as well as a CO2 incubator for culture of lymphocytes, a -700C freezer, a
scintillation counter for RT, and a liquid nitrogen tank for storage ofcells.
Procurement of human PBL for co-cultivation can be costly and difficult. The
medium needed for culture ofthe lymphocytes must be supplemented with fetal bovine
serum, interleukin 2, and anti-human interferon. Reagents for the RT assay include
template primer and 3H-labeled deoxythymidine triphosphate. Proper disposal of
radioactive isotopes is also expensive. Finally, a highly skilled technologist is essential,
and cultures must be maintained for at least four weeks with frequent refeeding and
testing for virus.
Recovery Rate In early attempts, HIV-1 could be isolated from only 30-89
percent of antibody-positive patients [13,14]. Furthermore, virus recovery varied with
the stage ofdisease, with virus harder to isolate in the early stages when culture would
be of most use. Recent reports indicate that it is possible to cultivate HIV-1 from close
to 100 percent of those patients in whom the presence ofdetectable antibody to HIV-1
proves infection with this virus [13,14,15].
Recent Developments
Use ofFrozen PBL The finding that PBL from normal donors, as well as those
from patients' specimens, could be frozen and thawed before use has helped to ease the
logistical problems of availability and transport of PBL. Frozen cells from normal
donors, however, are somewhat less sensitive for isolation and therefore should be used
only when fresh cells are not available.
Balachandran et al. [16] reported that the susceptibility to HIV-1 infection was
similar for normal human donor PBL that had been stimulated with PHA for 72 hours
and either used fresh or after having been frozen in cryopreservative fluid and thawed.
They also found that PBL that were first cryopreserved and thawed, then subsequently
stimulated with PHA for 72 hours, also retained susceptibility to HIV-1 infection.
In clinical trials, HIV-1 was isolated from 15 of 15 AIDS patients with cryopre-
served PBL. In contrast, HIV-1 was isolated from 11 of 13 asymptomatic HIV-1
seropositive men using fresh PBL, but only 3 of 13 using cryopreserved PBL [16].
Further studies are needed to determine whether cultures for HIV-1 seropositive
asymptomatic patients must only be performed with fresh PBL.
Gallo et al. [11,17] compared isolation rates of HIV-1 from Ficoll-Hypaque
separated PBL from patients' specimens, before and after three freeze-and-thaw cycles
in RPMI 1640 medium containing 10 percent fetal bovine serum and 10 percent
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dimethylsulfoxide. There was no general effect on isolation rate, suggesting that, in the
case ofpatients' samples, frozen PBLwere as suitableas fresh PBL for HIV-1 isolation
attempts. Thus the problem of getting heparinized blood from the patient to the
laboratory within 24 hours of collection was solved by using frozen cells. After
separated PBL are frozen, they can easily be shipped to the laboratory on dry ice and
thawed for co-cultivation attempts whenever it is most convenient for the laboratory.
Micro-Techniques for Culture Castro et al. [14] reported that cultures in
smaller vessels with a high cell density per unit surface area yielded better virus
recovery than cultures in larger vessels and required fewer cells. This latter featurewas
particularly important in pediatric patients, from whom only small amounts of blood
were available. The majority of positive cultures (62.5 percent) were detected within
4-11 days of incubation, and the sensitivity of the method was such that one infected
lymphocyte in one million would be detected. The use of smaller culture vessels and
fewer cells also helped lower the cost ofcells and medium.
Improved Detection of Virus in Culture Supernate After cultures have been
initiated, they must be tested once or twice a week for the presence of virus. The
standard method ofHIV detection in culture supernate has been the assay for the viral
enzyme RT, instead of detection of viral cytopathic effect (CPE). Multinucleated
giant cells form in the cultured infected lymphocytes after four to six days [12], but
this process has not been a sensitive or consistent method ofdetecting the virus.
Two drawbacks to the RT assay have been specificity (i.e., ability to distinguish
HIV-1 RT from cellular polymerases and from RT ofother retroviruses, HTLV-1 and
II, and HIV-2 [12]) and the difficulty and cost of working with and disposing of
radioisotopes (3H). It has also been tedious to perform; however, some improvements
have been made. Spira et al. [18] reported that a micro method for assay of RT was
equal to the macro method and saved both time and reagents. Lee et al. [19] developed
a RT assay that gave a 20- to 40-fold increase in enzyme activity over the current
method for detection and was sensitive enough to detect as few as 250 HIV-1 particles
in culture medium.
Yet, in spite of these improvements, the RT assay remains difficult, and a better
assay for virus detection was sought. Feorino et al. [20] reported that an antigen
capture ELISA was 100-fold more sensitive than the RT assay in detecting HIV-1 in
cell culture. The test was specific only for HIV-1 and gave positive results more
quickly, with an average time of 5.9 days versus 9.6 days for the RT assay. Lee et al.
[21] reported in a subsequent study that the antigen capture ELISA was sensitive
enough to detect 75 virus particles as compared to 130 virus particles for the RT
assay.
Viscidi et al. [22] found that 50 percent ofvirus-containing cultures were identified
within nine days by antigen capture ELISA but within 14 days by the RT assay. Also,
in cultures sampled on several days, RT activity was detected intermittently, whereas
antigen levels did not decline after initial appearance. Jackson et al. [13] used the
antigen capture ELISA in place of the RT assay for HIV-1 cultures and showed
improved sensitivity. Burger et al. [23] also found that antigen capture ELISA was
superior to RT for monitoring HIV-1 cultures in clinical trials.
As a result of these studies and others [24,25], when only HIV-1 is being sought in
cell cultures, the antigen capture ELISA has now become the method of choice over
RT since it produces more sensitive and rapid results. Ifretroviruses other than HIV-1
are suspected, then the RT assay must also be performed.
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DETECTION OF HIV ANTIBODY
Advantages
Several types of serological tests for HIV-1 antibody are available (Table 1),
including ELISA [26], Western blot [27,28], immunofluorescence [29,30,31,32],
radioimmunoprecipitation [33,34], and hemagglutination [35]. All these tests can be
performed rapidly, with the most commonly used ELISA requiring two to five hours to
complete. In addition, all of the eight approved ELISAs have a sensitivity and
specificity of over 99 percent. The ELISA is also easily automated, which saves
personnel time and insures accurate pipetting and objective reading of results.
Furthermore, because it can be automated, the ELISA can be done at low cost.
Disadvantages
Antibodies to HIV-1 develop about 8-12 weeks after infection, creating a window
when early infection is not detectable by antibody [37,38]. Also, late in infection after
disease has developed, antibody to p24 decreases; however, this latter finding may be
useful in prognosis [39]. The sensitivity and specificity of ELISA is dependent upon
the prevalence of infection in the population tested, and for diagnostic purposes a
supplemental test such as Western blot, immunofluorescence, or the recombinant
ELISA (Table 1) is needed to confirm positive results. In newborns, the diagnosis of
HIV-1 infection by antibody tests can be complicated, because maternal antibodies
may cross the placenta and give a positive result even when the baby is not infected. A
disadvantage ofseveral antibody tests, such as Western blot and immunofluorescence,
is that interpretation is dependent upon subjective criteria.
Recent Developments
Standardization ofthe Western Blot Betterstandardization ofthe Western blot
(WB) procedure is anticipated through better dissemination of information on the
procedure and more consensus on interpretation ofbanding patterns [42]. In addition,
several commercial semi-automated WB procedures are now available.
ELISAs Using Recombinant Protein or Synthetic Peptides HIV-1 grown in
human lymphocytes is used as antigen for the standard ELISA. Thus, reaction of
antibody in the patients' serum to human cellular antigens contaminating the viral
antigen preparation is possible, giving rise to false-positive results. This problem has
been overcome by the use ofrecombinant viral proteins made in bacteria or yeast [43]
or synthetic peptides [44] as antigen in the ELISA.
Screening ofDried Blood Spots (DBS) Human whole blood dried on to filter
paper represents a potential important sample collection method for HIV antibody
testing. Reports so far show that testing of DBS from both adults and neonates is a
suitable technique for HIV-1 antibody screening using commonly available commer-
cial ELISAs [45].
Quick Membrane ELISA Several commercial companies (Abbott Laborato-
ries, Genetic Systems) are testing in small plastic format membrane ELISAs that give
results in minutes. They are easy to perform and are read by visualization of a color
pattern on the membrane. Thistechnique allows rapid testing in emergency rooms and
in countries where spectrophotometers are not readily available.
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ANTIGEN TESTING
Advantages
More Rapid than Culture The current status of antigen testing has been
recently summarized [46]. In 1986, commercial tests became available for direct
detection ofHIV-1 antigen in serum, plasma, and cerebrospinal fluid (CSF), using the
ELISA technique. A blocking antibody (so-called neutralization test) should be used
to confirm positive results. If overnight incubation is used, the ELISA takes 24-30
hours to complete as compared to four weeks for HIV-1 isolation in culture. Recently
introduced antigen detection kits do not require overnight incubation; thus the time
can be shortened to three to five hours. (Direct detection of HIV-1 antigen in patients'
samples should not be confused with detection of HIV-1 antigen in the supernate of
HIV-1-infected cultures, as was discussed earlier in this review.)
Indicator of Active Infection In contrast to antibody tests, a positive direct
antigen detection indicates active HIV-1 infection. Conversely, in healthy individuals
in low-risk groups with indeterminate WB results, a negative antigen test may provide
some reassurance.
Early Detection ofInfection Antigen detection allows the diagnosis of HIV-1
infection prior to antibody seroconversion, which may take longer than one year from
the time ofexposure [47]. Transient HIV-1 antigenemia has been linked to acute HIV
infection before the appearance of HIV-1 antibody [48].
It is not known what percentage of individuals will express HIV antigen in serum
during the interval between exposure and seroconversion.
Prognosis ofDiseaseState Detection ofHIV-1 antigen in serum has prognostic
significance. In one report, asymptomatic individuals who were serum antigen-positive
were 18 times more likely to progress to AIDS over a 21-month period [49]. A positive
HIV-1 antigen test obtained from infants' serum is useful in confirming HIV infection
[41]. An HIV-1 antigen test can also be helpful to differentiate between primary and
HIV-associated immunodeficiency syndromes in childhood, since the ability to
produce antibodies may be impaired in these children.
MonitoringDrug Treatment Monitoring HIV-1 antigen levels may be useful in
measuring the antiviral effect ofdrug therapy. Mean HIV-1 antigen levels have been
shown todecrease significantly over time in patients treated with zidovudine compared
with placebo-treated controls [50].
Disadvantages
The sensitivity ofthe HIV-1 antigen assay is poor ifone assumes that most ifnot all
HIV-1 antibody-positive individuals are infected. The sensitivity of the test improves
with clinical progression of disease, showing 4 percent positivity in asymptomatic
patients, 56 percent positivity in AIDS-related complex (ARC) patients, and 70
percent positivity in AIDS patients [51,52]. The detectable limit ofthe assay has been
reported to be between 50 and 100 pg/ml [53,54].
The reagents for antigen tests are more expensive than antibody testing and also
moreexpensive than RT for HIV-1 detection inculture. Furthermore, the FDA has not
yet (April 1989) approved this test for diagnostic use.
Recent Developments
New and revised antigen tests that claim a greater sensitivity have recently been
introduced. Coulter Immunology claims a limit ofdetection of 1.0-1.56 pg per well for
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HIV-1 and HIV-2 p24 core antigen. Further study is needed to evaluate the usefulness
ofthese improved tests.
NUCLEIC ACID DETECTION
Advantages
Retroviruses are so named because of the RNA-dependent DNA polymerase
(reverse transcriptase) that, during virus replication, synthesizes RNA into DNA. The
DNA may then either be transcribed into RNA for the genetic material ofnew viruses
or for translation into HIV-1 proteins. The HIV genome does not contain sequences
homologous to normal human DNA [56] or to HTLV-I or HTLV-II DNA to any
extent [57]. Thus, infected cells can be probed by labeled HIV-1 DNA or RNA
sequences to detect HIV-1 nucleic acid by several hybridization techniques. Although
direct detection of viral-specific nucleic acid in patient specimens is not especially
sensitive, various methods of in vitro amplification of viral nucleic acid, such as
polymerase chain reaction (PCR) [58,59,60], can make this test extremely sensitive.
By selecting the proper gene probe, the test can be extremely specific. Using this
methodology, viral DNA integrated into the cellular genome can also be detected to
prove latent infection with HIV.
Disadvantages
Techniques for nucleic acid detection are technically difficult and remain research
tools at the present time. In addition, much research must still bedone todeterminethe
significance ofnucleic acid detection results.
CONCLUDING REMARKS
The number and types of tools that a laboratory can use for diagnosis of HIV-1
infection have increased over the past five years, making the selection of the proper
tools in each case more difficult. At present, screening for HIV-1 infection is best
performed by the ELISA for HIV-1 antibody, with confirmation ofrepeatedly reactive
specimens by Western blot. When antibody results are indeterminate, resolution can
be attempted by use of the recombinant antibody ELISA. The ELISA for antigen
detection is indicated in cases of recent exposure to HIV-1, in neonates, to determine
prognosis of high-risk antibody-positive patients, and to monitor drug therapy. If
antigens tests are negative, virus isolation should be performed, since it is more
sensitive. Nucleic acid hybridization is still used only as a research tool.
Since the true clinical significance of each diagnostic tool lags behind its develop-
ment, the use of multiple tools will undoubtedly continue until the proper role for
each is determined. In the next five years, the routine diagnosis of HIV-1 may be
accomplished by as yet undiscovered methods.
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